Rafael Holdings Inc (RFL) Stock Price, Quote & News

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylat...

Industry: Real Estate Services

Sector: Real Estate

Phone: 212 658 1450

Website: www.rafaelholdings.com

Address:

520 Broad Street, Newark, United States

CaseOfTheYips1 Oct. 2 at 6:11 PM

$RFL last one from me. I just grabbed a few more crumbs to bring my DCA down to $6.90. With over 10k shares, let’s get that news and put some money back in my pocket!?!

2 · Reply

CaseOfTheYips1 Oct. 2 at 5:52 PM

$RFL for those wondering about next quarterly, RFL is usually late on the full year. October 30th and November 6th for the past 2 years respectively. If nothing else, that’s our next update…

0 · Reply

CaseOfTheYips1 Oct. 1 at 9:08 PM

$RFL October is here… when is our time? Btw, I Fing hate SAVA…

1 · Reply

Love_To_Learn Sep. 30 at 10:51 AM

$RFL $JAGX modifying the old reverse park job 1.09-1.12 for entire stock market for you and what is coming for u later and your updates

0 · Reply

Bjorn_Slippy Sep. 29 at 6:27 PM

$RFL i realise what i am about to write sits more in the hopium end of the spectrum given everything thats happened since cyth merged but i was reviewing the ”investment case” for me and some of the old faithful. Our confidence was built on 3 main pillars 1) Success of NPC trials that would put trappsol on the map 2) followed by Acceptance by the FDA to launch Trappsol straight into a Phase 2 trial for AD and the indication it might have a use here 3) The strong suggestion/evidence that cyclo was potentailly effective in treating Triple negative breast cancer and the coincidental interest of Mr Jones who has a stated a mission to cure cancers ( he is of Jewish background and chat gpt tells me european Jewish women have a 1 in 40 vs 1 in 400 chance in general population of carrying the gene that confers a higher risk of TNBC) None of this has been proven wrong yet and so we continue to wait

1 · Reply

Biotechnicity Sep. 25 at 4:24 PM

$RFL If the possible deal alluded to in earlier posts materializes then it will happen in the coming weeks (not to exceed three). The pump on the acquirer side has taken place ensuring their shares don’t dip too badly and can recover from any perceived weakness. Very little chance but a chance.

0 · Reply

Fashtrades Sep. 24 at 10:20 PM

$RFL .. Ok .. So send it already !!

0 · Reply

ButterCall Sep. 24 at 6:18 PM

$RFL Short term (12h) view. Curling off support.

0 · Reply

Moksi Sep. 24 at 3:12 AM

$RFL it’s time for news

0 · Reply

GDS_investing Sep. 23 at 2:38 PM

$SSKN great call her glta my followers still huge long now watch $VTVT next very low float only 640k Great company, huge potential and $RFL all for long runup

1 · Reply

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Jun 11, 2025, 7:00 AM EDT - 4 months ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 4, 2025, 4:01 PM EDT - 4 months ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

May 20, 2025, 4:01 PM EDT - 4 months ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 5 months ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 5 months ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 24, 2025, 4:15 PM EDT - 5 months ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Mar 26, 2025, 6:50 AM EDT - 6 months ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 13, 2025, 5:50 PM EDT - 7 months ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Feb 20, 2025, 4:35 PM EST - 8 months ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Dec 11, 2024, 7:00 AM EST - 10 months ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Nov 6, 2024, 7:14 PM EST - 11 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Jun 13, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

May 2, 2023, 8:12 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Mar 14, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Jul 6, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jun 16, 2022, 2:14 PM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 14, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 1, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022, 11:04 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Mar 17, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 11, 2022, 4:00 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 2:26 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Jan 21, 2022, 7:00 AM EST - 4 years ago

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

Jan 18, 2022, 8:30 AM EST - 4 years ago

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 6, 2022, 8:30 AM EST - 4 years ago

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

CaseOfTheYips1 Oct. 2 at 6:11 PM

$RFL last one from me. I just grabbed a few more crumbs to bring my DCA down to $6.90. With over 10k shares, let’s get that news and put some money back in my pocket!?!

2 · Reply

CaseOfTheYips1 Oct. 2 at 5:52 PM

$RFL for those wondering about next quarterly, RFL is usually late on the full year. October 30th and November 6th for the past 2 years respectively. If nothing else, that’s our next update…

0 · Reply

CaseOfTheYips1 Oct. 1 at 9:08 PM

$RFL October is here… when is our time? Btw, I Fing hate SAVA…

1 · Reply

Love_To_Learn Sep. 30 at 10:51 AM

$RFL $JAGX modifying the old reverse park job 1.09-1.12 for entire stock market for you and what is coming for u later and your updates

0 · Reply

Bjorn_Slippy Sep. 29 at 6:27 PM

1 · Reply

Biotechnicity Sep. 25 at 4:24 PM

0 · Reply

Fashtrades Sep. 24 at 10:20 PM

$RFL .. Ok .. So send it already !!

0 · Reply

ButterCall Sep. 24 at 6:18 PM

$RFL Short term (12h) view. Curling off support.

0 · Reply

Moksi Sep. 24 at 3:12 AM

$RFL it’s time for news

0 · Reply

GDS_investing Sep. 23 at 2:38 PM

$SSKN great call her glta my followers still huge long now watch $VTVT next very low float only 640k Great company, huge potential and $RFL all for long runup

1 · Reply

Biotechnicity Sep. 23 at 2:26 AM

$RFL Let’s go?

0 · Reply

Fashtrades Sep. 22 at 6:17 PM

$RFL .. Need more out of you .. Let’s goooo

0 · Reply

Moksi Sep. 22 at 3:31 AM

$RFL we need news

0 · Reply

Moksi Sep. 20 at 6:33 PM

$RFL

0 · Reply

sg44 Sep. 20 at 3:49 PM

$RFL if passed we can wait for 96 weeks and win PRV https://www.biospace.com/policy/hope-for-rare-pediatric-disease-voucher-reignited-as-house-bill-passes-committee

0 · Reply

Biotechnicity Sep. 19 at 5:55 PM

$RFL just a day early

0 · Reply

Pizzino Sep. 19 at 5:50 PM

$RFL looks like a stop loss rug pull

0 · Reply

Fashtrades Sep. 19 at 5:48 PM

$RFL .. shame we can’t hold even a day 😏

0 · Reply

GDS_investing Sep. 19 at 1:49 PM

$INVZ AWESOME call here glta my followers sold half position very very nice ! now add long $VTVT (floay only 640k) $SSKN and $RFL

0 · Reply

Love_To_Learn Sep. 19 at 10:19 AM

$RFL not requiring an infuser cuts down the dates by roughly 2 quarters based on your current setup overall

0 · Reply

Love_To_Learn Sep. 19 at 10:17 AM

$RFL that shrinks the duration of time long in general *

0 · Reply

Love_To_Learn Sep. 19 at 10:16 AM

$RFL good news is u wont require an infuser longs *

2 · Reply

Market Cap	48.42M
Revenue (ttm)	640,000.00
Net Income (ttm)	-34.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,376.56%
Debt to Equity Ratio	0.01

Volume	50,800
Avg Vol	120,084
Day's Range	N/A - N/A
Shares Out	35.09M
Stochastic %K	22%
Beta	0.85
Analysts	Strong Buy
Price Target	N/A